Just days after nabbing the $300 million Wendy’s account from Kirshenbaum Bond, Kaplan Thaler has now confirmed it’s locked a project for a drug produced by German pharma company Boehringer Ingelheim.
While the KT folks refused to comment beyond the Boehringer Ingelheim attachment, we hear the agency won the pitch for the drug Girosa, aka Flibanserin, which is reportedly used to treat Hypoactive Sexual Desire Disorder in women. Unsubstantiated rumors are afloat that the account is worth somewhere around $30 million and that Kaplan Thaler beat out pitches from CommonHealth, Grey, JWT and McCann.
Advertisement
More: “Kaplan Thaler Takes Home Wendy’s”